Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03693378 · ClinicalTrials.gov registry record
A Study of IMMray™ PanCan-d Test for Early Detection of Pancreatic Cancer in High-risk Groups
A clinical trial, sponsored by Immunovia.
- Completed
- Registry status
- 1,349
- Enrollment target
NCT03693378: Completed study, sponsored by Immunovia.
NCT03693378 is a clinical trial that has completed, run by Immunovia. The registered enrollment target is 1,349 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03693378 has completed, sponsored by Immunovia.
- COMPLETED
- Registry status
- 1,349 participants
- Enrollment target
Study Summary
PanFAM-1 is a clinical study for early detection of pancreatic cancer in high-risk groups. The goals of the study are to assess the performance and diagnostic accuracy of the IMMray™ PanCan-d test compared to standard-of-care imaging.
Primary Outcome
Demonstrate that the IMMray PanCan-d test is equal or better than the reference standard imaging procedures for early detection of PDAC in asymptomatic high risk individuals
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,349 participants |
| Start Date | 2016-01-19 |
| Est. Completion | 2021-11-12 |
What the finished NCT03693378 record still lists
NCT03693378 is an observational study that tracks outcomes without assigning an intervention. Its 1,349 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT03693378 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03693378 about?
NCT03693378 is a clinical study titled "A Study of IMMray™ PanCan-d Test for Early Detection of Pancreatic Cancer in High-risk Groups". PanFAM-1 is a clinical study for early detection of pancreatic cancer in high-risk groups. The goals of the study are to assess the performance and diagnostic accuracy of the IMMray™ PanCan-d test compared to standard-of-care imaging.
What is the current status of trial NCT03693378?
This trial is currently completed. The enrollment target is 1,349 participants. The study started on 2016-01-19. Estimated completion is 2021-11-12.
Who is sponsoring clinical trial NCT03693378?
This trial is sponsored by Immunovia, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06318169 · 1,350 participants · Phase 3
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- NCT06605404 · 1,350 participants
Pan-tumor MRD Study
- NCT06806163 · 1,350 participants · NA
Machine-Learning Prediction and Reducing Overdoses With EHR Nudges
- NCT06731608 · 1,344 participants · NA
OsteoPorotic fracTure preventION System (OPTIONS) Research Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI